Drug intelligence / Profile preview

CRB-2113

Development stage: Preclinical
Lead developer: China Resources Angde Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Unknown

Overview

CRB-2113 is a preclinical-stage monoclonal antibody being developed by China Resources Biopharmaceutical (and its subsidiary China Resources Angde Biopharmaceutical) for the treatment of autoimmune diseases, specifically systemic lupus erythematosus (SLE) and myasthenia gravis (MG). As of 2026, the drug is in preclinical development, with pharmacokinetics and efficacy studies being conducted in animal models of SLE and MG.

Other names: CRB2113CRB-2113CRB 2113

Beyond the preview

Go deeper on CRB-2113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRB-2113.

Explore the full profile